Satralizumab for NMOSD Linked to Infections, With Older Male Patients at Greater Risk A pharmacovigilance study revealed infections as a safety concern of satralizumab in NMOSD, with some subgroups at risk for poorer outcomes.

An analysis of #Satralizumab safety revealed increased infection risk and highlighted vulnerable subgroups of patients with neuromyelitis optica spectrum disorder (#NMOSD).

Read more: https://bit.ly/41sEM2U

#RareDisease #MedSky #NeuroSky #Neurology